PEAR Key Statistics, Chart & Performance
The current stock price of PEAR is 0.0292 USD. In the past month the price decreased by -86.07%. In the past year, price decreased by -99.38%.
PEAR Latest News, Press Relases and Analysis
PEAR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| VEEV | VEEVA SYSTEMS INC-CLASS A | 31.53 | 40.00B | ||
| DOCS | DOXIMITY INC-CLASS A | 30.74 | 9.44B | ||
| WAY | WAYSTAR HOLDING CORP | 26.67 | 6.82B | ||
| HTFL | HEARTFLOW INC | N/A | 2.57B | ||
| CERT | CERTARA INC | 17.28 | 1.38B | ||
| TDOC | TELADOC HEALTH INC | N/A | 1.23B | ||
| SDGR | SCHRODINGER INC | N/A | 1.21B | ||
| PHR | PHREESIA INC | N/A | 1.20B | ||
| CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | 626.25 | 1.06B | ||
| LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.06B | ||
| GDRX | GOODRX HOLDINGS INC-CLASS A | 7.74 | 919.86M | ||
| CTEV | CLARITEV CORP | N/A | 778.89M |
Related stock screener links
About PEAR
Company Profile
Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The company is headquartered in Boston, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2021-02-02. The firm is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases. Its products include reset, reSET-O and Somryst. The firm's reset product is indicated for the treatment of substance use disorder (SUD) related to alcohol, cannabis, cocaine and stimulants, such as monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The firm's Somryst product is the only software-based and guideline-recommended treatment for chronic insomnia. The Company’s pipeline consists of 14 product candidates, including candidates in psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal (GI), oncology, and cardiovascular. The firm focuses on psychiatric and neurologic conditions.
Company Info
PEAR THERAPEUTICS INC
200 State Street, 13Th Floor
Boston MASSACHUSETTS US
Employees: 200
Phone: 16469322774.0
PEAR THERAPEUTICS INC / PEAR FAQ
What does PEAR do?
Pear Therapeutics, Inc. is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDT), which use software to treat diseases directly. The company is headquartered in Boston, Massachusetts and currently employs 200 full-time employees. The company went IPO on 2021-02-02. The firm is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases. Its products include reset, reSET-O and Somryst. The firm's reset product is indicated for the treatment of substance use disorder (SUD) related to alcohol, cannabis, cocaine and stimulants, such as monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The firm's Somryst product is the only software-based and guideline-recommended treatment for chronic insomnia. The Company’s pipeline consists of 14 product candidates, including candidates in psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal (GI), oncology, and cardiovascular. The firm focuses on psychiatric and neurologic conditions.
Can you provide the latest stock price for PEAR THERAPEUTICS INC?
The current stock price of PEAR is 0.0292 USD. The price decreased by -38.91% in the last trading session.
What is the dividend status of PEAR THERAPEUTICS INC?
PEAR does not pay a dividend.
What is the ChartMill technical and fundamental rating of PEAR stock?
PEAR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of PEAR stock?
PEAR THERAPEUTICS INC (PEAR) operates in the Health Care sector and the Health Care Technology industry.
What is the market capitalization of PEAR stock?
PEAR THERAPEUTICS INC (PEAR) has a market capitalization of 4.17M USD. This makes PEAR a Nano Cap stock.
PEAR Technical Analysis
PEAR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PEAR. PEAR has a bad profitability rating. Also its financial health evaluation is rather negative.
PEAR Financial Highlights
Over the last trailing twelve months PEAR reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 11.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PEAR Forecast & Estimates
12 analysts have analysed PEAR and the average price target is 5.44 USD. This implies a price increase of 18530.03% is expected in the next year compared to the current price of 0.0292.
For the next year, analysts expect an EPS growth of 10% and a revenue growth 119.68% for PEAR